Newspaper Publication of unaudited financials results for the Quarter and Half Year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals has informed BSE that it published its unaudited financial results for the quarter and half year ended September 30, 2025 in two newspapers — Financial Express (English) and Nava Telangana (Telugu) on November 14, 2025, as required under Regulation 47 of the SEBI Listing Regulations. The same results are also available on the company's website (www.venmaxdrugs.com). The disclosure was signed by Whole Time Director Venkata Rao Sadhanala (DIN: 02906370). The actual financial figures are not legible in the newspaper clippings attached. This is essentially a procedural compliance filing confirming that the results were published in print as mandated by SEBI.
This is a routine regulatory compliance submission with no direct impact on shareholders or the stock price. The underlying Q2/H1 FY26 financial results would have been filed earlier with the exchanges via the separate financial results filing, and investors should refer to that document for actual numbers and performance details.